|4Nov 5, 6:05 AM ET

OYSTER POINT PHARMA I, LLC 4

4 · Oyster Point Pharma, Inc. · Filed Nov 5, 2019

Insider Transaction Report

Form 4
Period: 2019-11-04
Transactions
  • Conversion

    Common Stock, par value $0.001 per share

    2019-11-04+955,392955,392 total
  • Conversion

    Series B Convertible Preferred Stock

    2019-11-04955,3920 total
    Common Stock, par value $0.001 per share (955,392 underlying)
Footnotes (2)
  • [F1]These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date.
  • [F2]Consists of 955,392 shares of common stock beneficially owned by Oyster Point Pharma I, LLC. William J. Link, as a managing partner of Oyster Point Pharma I, L.L.C., may be deemed to share voting and dispositive power over the shares held by Oyster Point Pharma I, LLC.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION